Related Experiment Video
Updated: May 7, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
17.2K
Tumor microenvironment and immunotherapy for triple-negative breast cancer
Zijie Guo1,2, Ziyu Zhu1,2, Xixi Lin1,2
1Department of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, 310016, Zhejiang, China.
Biomarker Research
|December 31, 2024
Summary
Triple-negative breast cancer (TNBC) is aggressive, challenging conventional treatments. Understanding the tumor microenvironment (TME) is key to improving immunotherapy effectiveness and identifying new biomarkers for TNBC patients.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Triple-negative breast cancer (TNBC) presents significant clinical challenges due to its aggressive nature and limited targeted therapies.
- The tumor microenvironment (TME) is increasingly recognized for its critical role in TNBC progression and response to treatment.
- Immunotherapy, particularly immune checkpoint inhibitors, shows promise but requires a deeper understanding of TME interactions.
Purpose of the Study:
- To review the complex interplay between the tumor microenvironment (TME) and immunotherapy in triple-negative breast cancer (TNBC).
- To analyze the TME's influence on immunotherapy efficacy and its potential as both a therapeutic target and a prognostic biomarker.
- To provide insights for developing enhanced therapeutic strategies and patient stratification methods for TNBC.
Main Methods:
- Literature review focusing on the characteristics and composition of the TME in TNBC.
- Analysis of existing data on TME components, including immune cells, stromal cells, and cytokines.
- Examination of the mechanisms underlying TME-immunotherapy interactions in TNBC.
Main Results:
- The TME significantly impacts TNBC progression and response to immunotherapy, characterized by high levels of tumor-infiltrating lymphocytes and immune checkpoint proteins.
- The complexity of the TME offers multiple avenues for therapeutic intervention and biomarker development.
- Understanding TME dynamics is crucial for optimizing current immunotherapies and exploring novel treatment strategies.
Conclusions:
- The tumor microenvironment (TME) is a critical determinant of immunotherapy success in triple-negative breast cancer (TNBC).
- Targeting TME components and utilizing TME characteristics as biomarkers can significantly improve treatment outcomes and patient stratification.
- Further research into TME-immunotherapy interactions is essential for advancing TNBC care.
Related Concept Videos
02:17The Tumor Microenvironment
6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
01:27Tumor Immunotherapy
394
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394